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Abstract.
Background: Prior diagnosis of Alzheimer’s disease (AD) among patients later diagnosed with vascular dementia (VaD)
has been associated with excess costs, suggesting potential benefits of earlier rule-out of AD diagnosis.
Objective: To investigate whether prior diagnosis with AD among patients with VaD is associated with excess costs in the
UK.
Methods: Patients with a final VaD diagnosis, continuous data visibility for ≥6 months prior to index date, and linkage to
Hospital Episode Statistics data were retrospectively selected from de-identified Clinical Practice Research Datalink data.
Patients with AD diagnosis before a final VaD diagnosis were matched to similar patients with no prior AD diagnosis using
propensity score methods. Annual excess healthcare costs were calculated for 5 years post-index, stratified by time to final
diagnosis.
Results: Of 9,311 patients with VaD, 508 (6%) had prior AD diagnosis with a median time to VaD diagnosis exceeding 2
years from index date. Over the entire follow-up period, patients with prior AD diagnosis had accumulated healthcare costs
that were approximately GBP2,000 higher than those for matched counterparts (mostly due to higher hospitalization costs).
Cost differentials peaked particularly in the period including the final VaD diagnosis, with excess costs quickly declining
thereafter.
Conclusion: Potential misdiagnosis of AD among UK patients with VaD resulted in substantial excess costs. The decline in
excess costs following a final VaD diagnosis suggests potential benefits from earlier rule-out of AD.
Keywords: Alzheimer’s disease, cost and cost analysis, diagnosis, health resources, vascular dementia
INTRODUCTION
The Alzheimer’s Society in the UK estimates that
1 in 14 (∼7%) of the UK population aged 65 years
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or over currently has some form of dementia [1].
Alzheimer’s disease (AD) is the most common cause
of dementia, accounting for approximately 62% of all
dementias in the UK, followed by vascular dementia
(VaD) at 17% and mixed dementia at 10% [1]. Other
less common causes of dementia include dementia
with Lewy bodies (4%) and frontotemporal demen-
tias (2%). The Society also estimates that the annual
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cost of care for individuals with dementia in the UK
exceeds GBP26 billion, 44% of which is accounted
for by ‘unpaid’, informal care provided by family
members and other caregivers [1].
The diagnosis and management of patients with
dementia can be challenging due to potential over-
lap in the clinical presentations of various dementia
etiologies [2]. Indeed, the rate of misdiagnosis for
multiple types of dementia is substantial in both clin-
ical and research settings, even when strict diagnostic
criteria are used, as shown by neuropathological
and neuroimaging evaluations [3–5]. In a recent
assessment of US Medicare beneficiaries who were
eventually diagnosed with VaD, Hunter et al. found
that a substantial proportion (17%) had previously
been misdiagnosed with AD [6]. Hence, additional
testing may be necessary to accurately diagnose the
cause of any cognitive impairment detected by clini-
cal assessment [7]. An accurate and timely diagnosis
is an important first step for patients, families, physi-
cians, and policy makers alike, as it helps ensure
that the patient’s prognosis, treatment, and overall
management are appropriate.
The above-mentioned study by Hunter et al. [6]
evaluated the medical costs among patients eventu-
ally diagnosed with VaD who had been previously
misdiagnosed with AD compared with costs among
similar matched patients with no prior AD diagnosis
[6]. Those with a history of AD diagnosis incurred
significantly higher medical costs until a final diag-
nosis of VaD, following which the costs for the two
groups eventually converged. Because of limitations
in the data source, this US study was unable to
include information relating to use of prescription
drugs. The primary objectives of the present study
were to evaluate the patterns of resource use and
costs, including those associated with prescription
drug use, in patients with VaD and prior AD diagnosis
versus those with no prior AD diagnosis, and to deter-
mine whether a potential misdiagnosis of AD among
patients with a final diagnosis of VaD is associated
with excess costs in the UK.
MATERIALS AND METHODS
Data sources
The study was conducted using data from the
Clinical Practice Research DataLink (CPRD), which
provides information about medical diagnoses (based
on Read codes), laboratory testing, and medica-
tions prescribed by primary care physicians for over
5 million active beneficiaries [8]. In addition, for
about 55% of the beneficiaries in CPRD, detailed
records on hospitalizations, including medical diag-
noses (based on International Classiﬁcation of
Diseases 10th revision [ICD-10] coding) and pro-
cedures, were obtained from Hospital Episodes
Statistics (HES) data [9]. Mortality data were
obtained from the Office of National Statistics (ONS)
[9]. The study protocol and statistical analysis plan
were developed a priori and approved by the Inde-
pendent Scientific Advisory Committee for MHRA
Database Research (protocol number 13 160R).
Healthcare cost data were not directly available
from the CPRD or HES datasets. These were esti-
mated as the product of frequency of use of a particu-
lar medical service (as observed in CPRD/HES) and
the unit cost associated with that service. Specifically,
the unit costs for medical services used by patients
in the primary care setting were obtained from the
annually published Unit Costs of Health & Social
Care publication, prepared by the Personal Social
Services Research Unit (PSSRU) [10]. The unit costs
for hospitalizations were estimated using the unit
costs associated with healthcare resource groups for
various hospital spells (a spell consisted of one or
more consecutive and/or overlapping hospitalization
episodes), as obtained from the National Schedule
of Reference Costs for UK National Health Service
(NHS) trusts and NHS foundation trusts [11]. The
unit costs for referrals and laboratory/diagnostic tests
were also estimated using the National Schedule of
Reference Costs for NHS. Finally, prescription med-
ication use in the study was captured as recorded in
the CPRD [8], and the unit costs of these medications
were estimated using data from First Databank [12].
All costs were estimated in 2013 British pounds
(GBP), adjusting for inflation using the Consumer
Price Inﬂation Reference Tables published by the
ONS [13]; analyses were conducted from the per-
spective of the UK NHS.
Study sample
A cohort of patients with a diagnosis of VaD was
identified as follows: First, all patients with a diagno-
sis of dementia (AD, VaD, frontotemporal dementia,
dementia with Lewy bodies, normal-pressure hydro-
cephalus, and Parkinson’s dementia) or any diagnosis
or symptom code for cognitive decline (other than
the specific dementias mentioned above, e.g., senile
dementia, presenile dementia, unspecified dementia)
were identified from CPRD data using Read and ICD-
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10 codes (Fig. 1; see Supplementary Tables 1 and 2
for relevant Read and ICD-10 codes) and linked to
HES data. Then those patients with a VaD diagnosis
in their most recent dementia record were selected for
inclusion in the study. In order to eliminate patients
with mixed dementias to as great an extent as possi-
ble, those with records of concomitant or interspersed
diagnoses for different types of dementia between
their first and last diagnoses were excluded: Specif-
ically, to be included in the study, patients were
required to have no other dementia diagnoses (includ-
ing AD) after the most recent VaD diagnosis over
up to 5 years of follow up. Additionally, patients
with multiple records of VaD were required to have
no diagnosis for another type of dementia between
their first and last VaD diagnoses; the first of the two
consecutive diagnoses was defined as the final diag-
nosis of VaD (Fig. 2). Among the patients with VaD
selected for the study, the index date was defined
as the date of the first VaD diagnosis or an earlier
observed diagnosis of a dementia-like condition or
cognitive decline, in order to follow patients from the
first observed evidence of dementia symptom onset.
Patients were additionally required to have data avail-
able for 6 months prior to and including their index
date (baseline period), and were followed until cen-
sored (see Fig. 2).
The primary aim of this analysis was to study
the differences in medical resource use and costs
for patients with a final diagnosis of VaD who were
Fig. 1. Derivation of study cohorts. ∗To reduce the likelihood of mixed dementias, patients with multiple vascular dementia (VaD) diagnoses
were removed if they had an indication of other types of dementia (e.g., dementia with Lewy bodies) between their first and last VaD
diagnoses. AD, Alzheimer’s disease; CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics; ICD-10, International
Classification of Diseases.
Fig. 2. Study design. AD, Alzheimer’s disease; VaD, vascular dementia.
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previously diagnosed with AD relative to those with
no prior AD diagnosis. Therefore, patients with a final
diagnosis of VaD were separated into two groups
based on the presence or absence of AD diagnosis
prior to final diagnosis of VaD (Fig. 1).
Outcomes and analytical approach
Baseline patient characteristics
Information was collected on the following patient
characteristics during the baseline period: Patient
demographics, comorbidity profile (using the Charl-
son Comorbidity Index [CCI], calculated as detailed
in Khan et al. [14] and Quan et al. [15]), and
healthcare resource use (including medication use,
clinician visits, hospitalizations, and referrals to
specialists). These characteristics were compared
between patients with VaD with and without prior
AD diagnosis using Chi-squared tests for categorical
variables and Wilcoxon rank-sum tests for continuous
variables.
Propensity score matching
To account for observable confounding factors,
the two groups were matched using propensity score
techniques. First, the likelihood of being diagnosed
with AD based on observed baseline characteristics
was estimated using logistic regression models, with
indicator of AD as the dependent variable and patient
demographics, year of index date, medication use,
and medical resource use as the independent vari-
ables. The two groups were then matched 1:1 using
a propensity score-based ‘optimal’ matching method
employing a caliper equal to one-fourth of the stan-
dard deviation of the propensity scores [16, 17]. To
enable evaluation of excess medical resource use and
costs associated with prior AD diagnosis over time,
patients were also matched on length of follow-up. In
particular, comparator patients were required to have
at least the same length of follow-up (in full years) as
their matched cases.
Following matching, patient characteristics were
re-evaluated using McNemar’s tests for categorical
variables and Wilcoxon signed rank tests for con-
tinuous variables to determine whether observable
differences remained between the matched cohorts.
Time to ﬁnal diagnosis of vascular dementia
The time from index date to final diagnosis of VaD
(in months) was estimated for both cohorts (prior
to matching) using Kaplan–Meier survival analyses;
log-rank tests were used to detect any statistical
significance between cohorts. Additionally, the pro-
portional hazard of delay in a final diagnosis of VaD
due to the presence of prior AD diagnosis was esti-
mated before matching using a Cox proportional
hazard model that accounted for various baseline
patient characteristics.
Healthcare utilization and costs
Annual frequencies of medical services used over
time were compared between matched pairs for
up to 5 years post-index. The following categories
of resource use were evaluated: Clinical, surgi-
cal, telephone, and home consultations; referrals to
psychiatrists, neurologists, or gerontologists; hospi-
talizations; laboratory and diagnostic testing; and
medication use. The proportions of patients in each
group with any resource use in each category were
compared using McNemar’s tests for matched pairs.
Consultations and number of prescription medica-
tions were approximately log-normally distributed,
while the rest of the outcomes followed an approxi-
mate negative binomial distribution. As such, paired
t-tests were used to evaluate the statistical signifi-
cance of differences in the numbers of consultations
and prescription medications following log transfor-
mations, whereas generalized linear models with a
negative binomial distribution and log link were used
for other outcome measures.
Annual incremental costs (in GBP, year 2013 val-
ues) paid by the NHS to providers for medical
services and prescription drugs used by patients with
VaD and prior AD diagnosis, relative to their matched
controls, were estimated for up to 5 years post-index.
Annual excess costs in the years leading up to and
following final diagnosis of VaD were also estimated
for up to 5 years post-index. To avoid annualiza-
tion of partial years that might be disproportionately
affected by end-of-life care, the analysis for each year
of follow-up included only those patients observable
for the complete year.
The approach used to estimate the costs associ-
ated with each category of resource use is given in
Supplementary Table 3. If no use was recorded for
any resource, costs were assumed to be zero. Total
medical costs were estimated as the sum of costs
across all places of service examined. Total healthcare
costs were estimated as the sum of medical costs and
prescription drug costs. The statistical significance
of differences in costs between the two groups was
evaluated using bias-corrected bootstrapping.
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Sensitivity analyses
Sensitivity analyses were conducted to determine
the generalizability of the propensity score-matching
analysis (i.e., whether the exclusion of a subset of
patients from the analysis, because of matching,
affected findings) using multivariate modeling of
the entire pre-match sample. Risk-adjusted health-
care costs were estimated for the full sample (before
matching) using generalized linear regression models
with a log link and a gamma distribution of the error
term. Another sensitivity analysis was conducted in
which the index date was redefined as the date of
first AD diagnosis for patients with prior AD, and
as the date of final diagnosis of VaD for those with
no prior AD. The analyses were conducted for this
reoriented sample using similar baseline and follow-
up periods as those used for the core sample (i.e., a
6-month baseline period prior to the new index date
was used to evaluate patient characteristics and con-
duct propensity score matching, and annual follow-up
periods continued until the end of data availability
or the patient’s death). A final sensitivity analysis
was conducted to assess whether the presence of
depression could impact excess costs by estimating
excess costs among a subset of VaD patients with
no indication of depression (identified using Read
codes, ICD-10 codes, or prescriptions for antidepres-
sant medication) during the 6 months prior to their
index date. All models accounted for the same set of
baseline patient characteristics included in the
propensity score-matching analysis.
All analyses were performed using SAS version
9.3 (SAS Institute, Cary, NC, USA).
RESULTS
Sample characteristics
Of the 9,311 patients with VaD selected for inclu-
sion in the study, 508 (6%) had AD diagnosis prior to
final diagnosis of VaD (Fig. 2). For patients with prior
AD diagnosis, median time to final diagnosis of VaD
was approximately 2 years, compared with approxi-
mately 2 months for those with no prior AD diagnosis
(Fig. 3). Prior AD diagnosis was a significant predic-
tor of delay in VaD diagnosis, even after accounting
for other patient characteristics (hazard ratio = 0.54,
95% confidence interval [CI]: 0.49–0.59; p < 0.0001).
Of note, nearly 40% of the patients with no prior
AD diagnosis were diagnosed with VaD at the index
date.
Before matching, patients with prior AD diag-
nosis were significantly younger at the index date
than patients with no prior AD diagnosis (79.9 years
versus 81.4 years; p < 0.0001). In addition, patients
with prior AD diagnosis had longer follow-up (3.9
years versus 2.8 years; p < 0.0001) and lower rates
of comorbidities (CCI: 0.3 versus 0.5; p < 0.0001)
and were less likely to use medical services (in all
Fig. 3. Time to vascular dementia (VaD) diagnosis in patients with and without prior Alzheimer’s disease (AD) diagnosis prior to propensity
score matching. IQR, interquartile range.
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Table 1
Patient characteristics at baseline (during 6 months before the index event) before and after matching
Selected characteristics Pre-match Post-match
Prior AD No prior p-value1 Prior AD No prior p-value1
diagnosis AD diagnosis diagnosis AD diagnosis
(n = 508) (n = 8,803) (n = 502) (n = 502)
Age, years, mean (SD) 79.9 (7.4) 81.4 (7.3) <0.0001 79.9 (7.4) 79.4 (7.7) 0.2623
Male, % 39 40 0.5070 39 39 0.8985
Charlson Comorbidity Index, mean (SD)2 0.3 (0.7) 0.5 (1.0) <0.0001 0.2 (0.6) 0.3 (0.7) 0.1108
Years of follow-up, mean (SD) 3.9 (2.8) 2.8 (2.4) <0.0001 3.9 (2.7) 3.8 (2.6) 0.3511
Medical resource use, % with ≥1:
Hospitalization 19 29 <0.0001 19 20 0.9270
Emergency department visit 10 17 0.0003 10 11 0.9093
Clinician visit 94 97 0.0010 94 94 1.0000
Referral to specialist 33 41 0.0003 33 36 0.3496
Visit for diagnostic imaging 4 7 0.0039 4 4 0.7150
Medication use, % with ≥1 script for:
Any medication 93 96 0.0004 92 92 0.6276
Antihypertensive agents 59 70 <0.0001 58 57 0.5596
Analgesics 37 43 0.0034 37 38 0.8394
Statins 28 38 <0.0001 28 31 0.1821
Dementia agents 1 <1 0.0015 <1 0 –
Antidepressants 21 26 0.0092 21 21 0.7503
Antipsychotic agents 5 7 0.0156 5 3 0.2498
NSAIDs 18 16 0.3446 17 17 0.9334
Antidiabetes agents 11 13 0.1262 11 12 0.7029
Antiparkinsonian agents 1 2 0.2003 1 1 0.7055
Other 85 92 <0.0001 85 88 0.1470
1Statistical significance was evaluated using Wilcoxon rank sum tests for continuous variables and Chi-squared tests for categorical variables.
p < 0.05 was considered statistically significant; values that differ significantly are indicated by bold type. 2Calculated using previously
validated Read and ICD-10 codes [15] and Read codes [14]. See Supplementary Table 2 for a complete list of ICD-10 diagnosis codes. AD,
Alzheimer’s disease; ICD-10, International Classification of Diseases, 10th revision; NSAIDs, nonsteroidal anti-inflammatory drugs; SD,
standard deviation.
categories) or medications (in most categories) at
baseline than those with no prior AD diagnosis
(Table 1). Baseline differences were largely elimi-
nated following propensity score matching (Table 1).
The matched samples consisted of 502 matched pairs,
reflecting approximately 99% of the patients with
prior AD diagnosis.
Healthcare resource use and costs over time
Healthcare resource use
The mean number of consultations per patient
per year remained stable over time in both matched
groups (Table 2). By comparison, the mean number of
referrals to specialists decreased in both groups over
time, particularly for those with prior AD diagnosis,
who had significantly fewer referrals in years 4 and
5 post-index relative to their matched counterparts.
The mean number of days hospitalized decreased for
both groups at a similar rate during the first 3 years
post-index; however, during years 4 and 5, those with
prior AD diagnosis had a significantly higher number
of days hospitalized than the matched counterparts.
Numbers of hospital admissions from the emergency
department were also higher in patients with prior
diagnosis of AD during years 3–5, but did not differ
significantly from those in patients without prior AD
diagnosis.
In terms of medications, use of a number of classes
of drug increased from baseline during the follow-up
period, and their usage differed significantly between
patients with and without prior AD diagnosis. For
example, drugs for the treatment of dementia were
used by ∼1% of patients in the total sample at base-
line (Table1)andby16–26%ofpatientswithpriorAD
diagnosis and 3–6% of patients with no prior AD diag-
nosis for each year of follow-up. Similarly, in patients
with prior AD diagnosis, antipsychotic use increased
from5%atbaselineto20–26%foreachyearoffollow-
up, and in patients with no prior AD diagnosis this
usage increasedfrom3%atbaseline (matchedpopula-
tion) to14–21%foreachyearoffollow-up.Respective
increases in statin use were 28% to 35–44% and 31%
(matched population) to 42–54%.
Patients with prior AD diagnosis had a signifi-
cantly higher utilization of medications for dementia
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Table 2
Healthcare resource use by year of follow-up1,2
Year of follow-up Prior AD diagnosis No prior AD diagnosis p-value3
No. of consultations
Year 1 37.2 (22.4) 36.1 (20.9) 0.5328
Year 2 35.2 (21.8) 33.7 (20.7) 0.6157
Year 3 35.0 (22.7) 34.0 (19.8) 0.8501
Year 4 32.6 (19.4) 38.5 (23.3) 0.0031
Year 5 34.5 (24.2) 34.6 (19.6) 0.4923
No. of referrals
Year 1 1.5 (1.9) 1.4 (1.5) 0.1435
Year 2 0.9 (1.4) 0.8 (1.2) 0.5981
Year 3 0.8 (1.4) 0.8 (1.2) 0.8903
Year 4 0.6 (1.1) 1.1 (1.4) 0.0002
Year 5 0.6 (1.3) 0.9 (1.3) 0.0235
No. of days hospitalized
Year 1 21.4 (63.5) 22.4 (61.7) 0.8090
Year 2 12.9 (57.8) 18.3 (74.8) 0.1451
Year 3 12.4 (41.1) 8.8 (26.7) 0.2159
Year 4 19.1 (65.9) 7.5 (24.3) 0.0031
Year 5 18.9 (61.7) 8.9 (24.3) 0.0491
No. of admissions from
the emergency department
Year 1 0.4 (0.8) 0.5 (0.9) 0.3771
Year 2 0.3 (0.7) 0.3 (0.7) 0.5687
Year 3 0.4 (0.7) 0.3 (0.6) 0.1064
Year 4 0.4 (0.8) 0.3 (0.8) 0.4042
Year 5 0.4 (0.7) 0.3 (0.6) 0.2871
No. of prescriptions
Year 1 65.4 (79.3) 65.1 (68.5) 0.4036
Year 2 77.1 (93.5) 73.2 (72.1) 0.4630
Year 3 80.2 (93.3) 76.4 (73.4) 0.6280
Year 4 84.6 (93.7) 82.3 (76.7) 0.2950
Year 5 88.4 (89.9) 71.1 (49.8) 0.4611
Data are reported as means ± standard deviations. 1The follow-up period was defined as the period following, and
including, a patient’s index date, until the end of continuous eligibility or death. The index date was defined as the
date corresponding to the earliest diagnosis for cognitive decline. 2Patients with prior AD were matched one-to-one
to patients without prior AD using a propensity score model and the minimum length of follow-up. Propensity
scores were estimated using logistic regression models that accounted for patient demographics, year of index
diagnosis, select medical resource use, and medication use in the 6-month baseline period. 3Statistical significance
was evaluated using McNemar’s test for categorical variables. Paired t-tests were used to evaluate statistical
significance for the numbers of consultations and prescriptions following log transformations, and generalized
linear models with a negative binomial distribution and a log link were used for other outcome measures. p < 0.05
was considered statistically significant; values that differ significantly are indicated by bold type. Numbers of
matched pairs in each year of follow-up were as follows: year 1, n = 446; year 2, n = 366; year 3, n = 270; year 4,
n = 207; year 5, n = 138. Means were calculated for the entire sample for a given year (including those with no
resource use). AD, Alzheimer’s disease.
(in terms of number of patients with at least one pre-
scription and the mean number of prescriptions) than
patients with no prior AD diagnosis for each year of
the study. In terms of number of patients with at least
oneprescription,patientswithpriorADdiagnosisalso
had a significantly higher utilization of antipsychotics
during years 1 and 3, and a lower utilization of statins
during years 1, 2, and 4, than patients without this
diagnosis (p < 0.05 for all). Anti-parkinsonian drug
use (number of patients with at least one prescription)
was higher in patients with prior AD diagnosis than
those with no prior AD diagnosis at year 3, and was
the only other type of drug usage to differ significantly
between the two patient groups during follow-up.
Overall, however, the number of all-cause prescrip-
tions was similar across the two groups over time
(Table 2). Significant differences in the mean num-
bers of laboratory and non-imaging diagnostic tests
conducted over time appeared only after year 3, with
patients with no prior AD diagnosis requiring sig-
nificantly (p < 0.05) higher numbers of biochemistry,
microbiology, and non-imaging diagnostic tests in
year 4 (data not shown) and higher numbers of micro-
biology tests in year 5 (data not shown).
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Table 3
Healthcare costs (in 2013 British pounds [GBP])1,2,3 over entire length of follow-up4
Prior AD No prior p-value5
diagnosis AD diagnosis
(n = 502) (n = 502)
Total healthcare costs 20, 179 (15, 757) 17, 896 (17, 417) 0.0212
Medical costs 17, 414 (13, 966) 15, 732 (16, 170) 0.0692
Medications 2, 765 (4, 160) 2, 164 (3, 769) 0.0070
Consultations 4, 562 (3, 811) 4, 545 (4, 265) 0.9038
Clinical consultations 373 (528) 414 (706) 0.2316
Surgery consultation 3, 635 (3, 059) 3, 491 (3, 142) 0.2923
Telephone consultations 123 (209) 138 (354) 0.3640
Home visits 432 (972) 501 (1, 413) 0.3542
Referrals 440 (541) 451 (635) 0.7533
Hospitalizations 11, 997 (11, 981) 10, 310 (14, 736) 0.0502
Admissions from ED 6, 440 (6, 841) 5, 725 (6, 679) 0.0841
Tests
Diagnostic imaging 66 (105) 71 (122) 0.5064
Laboratory tests 273 (264) 284 (313) 0.4938
Non-imaging diagnostic tests 76 (150) 72 (194) 0.7004
Medications 2, 765 (4, 160) 2, 164 (3, 769) 0.0070
Analgesics 109 (403) 106 (399) 0.8479
Dementia agents 578 (1, 364) 130 (728) <0.0001
Antidepressants 71 (205) 82 (271) 0.4148
Antidiabetic agents 119 (833) 97 (617) 0.5911
Antihypertensive agents 228 (395) 206 (335) 0.2549
Antiparkinsonian agents 10 (80) 7 (57) 0.4664
Antipsychotics 221 (882) 147 (595) 0.0834
NSAIDs 21 (85) 24 (111) 0.6179
Statins 123 (396) 99 (287) 0.2288
Other medications 1, 286 (3, 192) 1, 267 (2, 917) 0.8861
AD, Alzheimer’s disease; ED, emergency department; NSAIDs, nonsteroidal anti-inflammatory drugs. Data are
reported as means ± standard deviations. 1The follow-up period was defined as the period following, and including,
a patient’s index date, until the end of continuous eligibility or death. The index date was defined as the date
corresponding to the earliest diagnosis for cognitive decline. 2Patients with prior AD were matched one-to-one
to patients without prior AD using a propensity score model and the minimum length of follow-up. Propensity
scores were estimated using logistic regression models that accounted for patient demographics, year of index
diagnosis, select medical resource use, and medication use in the 6-month baseline period. 3Costs are rounded
to the nearest whole pound (2013 GBP). 4Costs are observed over the entire length of follow-up, which may
vary from patient to patient. 5Statistical significance was evaluated using bias-adjusted bootstrapping. p < 0.05 was
considered statistically significant; values that differ significantly are indicated by bold type.
Healthcare costs
Over the entire follow-up period, mean total health-
care costs were significantly higher in patients with
prior AD diagnosis than in those with no prior AD
diagnosis (GBP20,179 versus GBP17,896, p < 0.05
[Table 3]). In each year post-index, patients with prior
AD diagnosis had higher total healthcare costs than
those without prior AD diagnosis, although the dif-
ferences were only statistically significant in year 3
(GBP4,080 versus GBP3,273, p < 0.05) (see Fig. 4).
Medical costs accounted for more than 85% of total
healthcare costs in both groups, primarily due to
the cost of hospitalizations. Despite similar num-
bers of prescriptions overall, patients with prior AD
diagnosis had significantly higher medication costs
than their matched counterparts. Examination of the
results by time to VaD diagnosis reveals important
variation. In particular, patients with prior AD diag-
nosis incurred significantly higher healthcare costs in
the period including their final diagnosis of VaD than
patients with no prior AD diagnosis. Excess health-
care costs for patients with prior AD diagnosis peaked
at approximately GBP3,000 per patient per year when
stratified by time to final diagnosis (Fig. 5). Follow-
ing final diagnosis of VaD, the costs of patients with
prior AD diagnosis tended to converge with the costs
of patients with no prior AD diagnosis.
Sensitivity analyses
Sensitivity analyses confirmed the generalizability
of these findings and that the results were robust with
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Fig. 4. Mean total healthcare costs over time. All costs were estimated in 2013 British pounds (GBP). AD, Alzheimer’s disease. ∗p < 0.05.
Fig. 5. Excess annual costs during the follow-up period among matched patients with and without prior diagnosis of Alzheimer’s disease:
Stratified by time to vascular disease diagnosis. All costs were estimated in 2013 British pounds (GBP). ∗ p < 0.05.
regard to study index date and presence of depression.
With respect to the effect of the propensity score-
matching analysis, patients with prior AD diagnosis
continued to have significantly higher healthcare
costs, but only up until the time they received a final
diagnosis.
DISCUSSION
The results of this study suggest that 6% of patients
with VaD in the UK are possibly initially misdiag-
nosed as having AD. While lower than other existing
estimates (17% [6]), this figure still represents a
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substantial number of patients given the prevalence
of VaD (about 1.2% of the elderly UK population)
[1]. For half of the patients with a prior AD diagno-
sis, a final diagnosis of VaD may have been delayed
for at least 2 years after initial presentation with
symptoms of cognitive decline, leaving patients sub-
ject to extended periods of possibly suboptimal care.
Patients with VaD and prior AD diagnosis incurred
higher levels of medical resource utilization and asso-
ciated costs over time.
There are two potential explanations for the find-
ing that patients with VaD and prior AD diagnosis
incurred higher levels of medical resource utiliza-
tion and associated costs than those with no prior AD
diagnosis. The first is that, despite removing patients
with diagnosis patterns suggestive of mixed VaD and
AD during the sample selection, the study sample
continued to capture patients with mixed VaD and
AD, and that these patients are simply more complex
than patients with VaD alone, their treatment requir-
ing higher levels of medical resource use and costs. A
second possibility is that the study captured patients
with VaD who were initially diagnosed with AD, and
that the excess resource utilization and costs are due
to clinical care associated with this initial AD diagno-
sis. For example, physicians with lower confidence in
a certain diagnosis may increase the frequency with
which they interact with their patients to collect addi-
tional data. Similarly, if patients with VaD are initially
diagnosed with AD they may possibly receive therapy
that is inappropriate and, hence, suboptimal for their
condition; as a result, they (and their caregivers) may
be more likely to return to their physicians to seek fur-
ther evaluation. If their symptoms are not optimally
treated, these patients may also be at increased risk
of accidental injury.
The two hypotheses need not be mutually exclu-
sive, but the analysis of costs stratified by time to
VaD diagnosis is useful in determining which is more
likely. As detailed above, while the overall medical
resource use and costs over time are somewhat higher
among patients with VaD and prior AD diagnosis,
these findings mask important variation. The strati-
fied analysis reveals a strong correlation between the
timing of the change in diagnosis from AD to VaD and
spikes in excess costs. These spikes are not consis-
tent with a profile of patients who are more complex,
as such patients would be expected to incur higher
costs over extended periods of time. Rather, the spikes
in excess costs are consistent with a more thorough
evaluation of the patients around the time that their
VaD diagnosis is resolved. The fact that excess costs
quickly dissipate in subsequent years suggests that
once a final diagnosis of VaD was made these patients
no longer required medical care above and beyond
that received by their matched counterparts.
These findings are largely consistent with those of
the aforementioned US study [6], which used data
from Medicare beneficiaries with VaD and similarly
found a strong correlation between the timing of the
final diagnosis of VaD and spikes in excess costs.
However, unlike the US study, excess costs in our
study are more concentrated in the period in which
the VaD diagnosis is resolved, rather than gradually
increasing leading up to the period of final diagnosis
of VaD.
Furthermore, our findings illustrate that a prior AD
diagnosis in a patient with VaD can impact treatment.
For example, use of drugs for the treatment of demen-
tia was significantly higher in patients with prior
AD diagnosis than in those with no prior AD diag-
nosis. These medications (e.g., acetylcholinesterase
inhibitors and memantine) have proven efficacy in
patients with AD [18] and hence their use in patients
initially diagnosed with AD is unsurprising; how-
ever, their effects on cognition in patients with VaD
have been shown to be weaker, and of uncertain
clinical significance [18–20]. In addition, current
National Institute for Health and Care Excellence
(NICE) guidelines recommend the use of acetyl-
cholinesterase inhibitors and memantine in patients
with AD but not VaD [21]. Hence, a prior AD diag-
nosis in a patient with VaD may result in possibly
suboptimal care and incur significant unnecessary
costs.
In the matched cohorts, about 30% of patients were
prescribed statins during the baseline period, irre-
spective of prior AD diagnosis in our study. This
proportion increased to 35–44% in patients with prior
AD diagnosis and 42–54% of patients without prior
AD diagnosis, and is slightly higher than the 23% of
patients aged 75 years and over who were prescribed
statins for primary prevention in a recent retrospective
cross-sectional study conducted in a typical primary
care population at 19 general practices in the UK
[22]. This could suggest that statins were additionally
being used to prevent and/or slow the progression of
AD/VaD in our patient population. Although NICE
does not currently recommend the use of statins for
the primary prevention of dementia [21], it has been
postulated that treatment with lipid-lowering drugs,
such as statins, could lessen the risk of dementia
and/or slow progression of the disease [23], partic-
ularly VaD [24]. The results of studies have been
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conflicting [23, 25], but many researchers consider
there is growing evidence that statins may potentially
reduce the incidence of dementia [26].
Also of note is our finding that, at baseline, up
to 7% of patients with or without prior AD diagno-
sis were prescribed an antipsychotic, increasing in
each year of follow-up to 20–26% in patients with
prior AD diagnosis and to 14–21% in patients with
no prior AD diagnosis. The vast majority of antipsy-
chotic prescriptions in individuals with dementia are
considered inappropriate [27], and antipsychotics are
not currently recommended for use in patients with
AD or VaD [21]. In support of the UK Government’s
commitment to reduce the inappropriate prescribing
of antipsychotic medication for people with demen-
tia, recent audit data indicate a 52% reduction in
the number of people with dementia receiving an
antipsychotic prescription between 2008 and 2011
[28]. Nevertheless, the audit found that 7% of people
with dementia were still being prescribed antipsy-
chotic medication, a figure in line with that reported
during the baseline period of this study.
Study strengths and limitations
This study used CPRD data linked with HES
and ONS, thereby incorporating patients’ hospitaliza-
tion and mortality information together with clinical
records and medication data. Further, the study design
ascertained that patients with clear patterns of poten-
tial mixed dementia (i.e., with intertwined records
of multiple dementia etiologies) were not included
in the analyses. In addition, comparing the costs
of patients with prior AD diagnosis with those of
matched controls with no prior AD diagnosis allowed
us to quantify the incremental costs associated with
potential misdiagnosis of AD in a patient with VaD.
To our knowledge, this is the first study to do so in the
UK CPRD population.
Limitations of this study include its reliance on the
Read codes and ICD-10 codes used within the CPRD
and HES administrative records datasets, respec-
tively. These codes are retrieved from electronic
health records and hospital admission records and do
not contain information necessary to confirm clinical
diagnoses, severity of illness, or physician interpre-
tation. Hence, it is possible that patients with mixed
dementia were not fully excluded from the study
cohort, leading to greater variability in the results.
It is also possible that patients with AD developing
an abrupt decline in cognitive function following a
stroke may have been categorized as having VaD.
However, as the presence of both of these types of
patients among the study cohort would have blurred
potential differences between patients with VaD with
and without prior AD diagnosis, we consider it likely
that the difference in estimated costs between the two
groups identified in this study would be an underes-
timation rather than an overestimation.
Additionally, records within CPRD contain infor-
mation only about medications prescribed and not
medications dispensed. As a result, the findings
related to medication use and costs rely on an assump-
tion that all medications prescribed are dispensed and
used as indicated. Prescription medication use in the
study was captured as recorded in the CPRD; hence,
no information on the rationale for medication pre-
scription is available. Over-the-counter medications,
out-of-pocket expenses, and informal care are also
not captured within the CPRD framework.
With regard to costs, the analyses are based on
applying the reference unit costs provided by the NHS
to the resource utilization observed in the data. The
CPRDdatadonotcaptureactualreimbursementsfrom
the NHS to providers of medical services. In addi-
tion, the accumulated cost figures need to be treated
with caution since sample sizes changed from one
year to another, making interpretation difficult; also,
the potential differential relation between attrition and
outcomes across cohorts may differ over time.
Finally, the propensity score-matching approach
effectively controls for observed differences within
the dataset but cannot address unobserved hetero-
geneity in patient characteristics across cohorts. It
is also possible that matching patients on length of
follow-up, thereby requiring that comparator patients
have at least the same length of follow-up as their
matched cases, could introduce bias if prior diagno-
sis of AD was associated with differential mortality.
Consequently, we evaluated the predictors of mor-
tality among the sample of patients with VaD using
a Cox proportional hazard model. Controlling for
other observable characteristics, we found that prior
AD diagnosis was not a significant predictor of time
to death (hazard ratio = 0.99, 95% CI 0.87–1.12).
Therefore, based on these findings, we assumed that
requiring matched pairs to have similar lengths of
follow-up would not bias the analysis.
CONCLUSIONS
The substantial excess costs associated with the
potential misdiagnosis of AD among patients with
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VaD—and the decline of those costs following the
final diagnosis of VaD—suggest potential value for
timely and accurate diagnosis. Technologies that
support earlier rule-out of AD in patients with cog-
nitive decline, such as amyloid positron emission
tomography tracers, need to be further evaluated in
this context. Given that some portion of the excess
medical resource use and costs (including possi-
ble suboptimal care) estimated in this study can
be avoided through earlier rule-out of AD among
patients with VaD, such technologies, when used
according to current UK guidelines, may be asso-
ciated with substantial cost offsets from the NHS
perspective.
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